

Appln. Serial No. 09/530,298

2

Docket No. 500862000700

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

The List of Claims

1. (currently amended) A compound of formula E-C_a-R-C_b-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, C_b and C_a are optional first and second connecting respectively, and A is an affinity group comprising any molecule or part of a molecule possessing specific binding determinants for a target molecule ~~having an affinity for human serum albumin, wherein affinity group A comprises a sequence of amino acid residues O₁-O₂-X₁-X₂-B in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids.~~
2. (previously amended) A compound according to claim 58, wherein amino acid residue O₁ is selected from the group consisting of phenylalanine, arginine, glutamine, tyrosine, glutamic acid and tryptophan; amino acid residue O₂ is selected from the group consisting of leucine, arginine, glutamic acid, tryptophan and phenylalanine; amino acid residue X₁ is selected from the group consisting of phenylalanine, tryptophan, methionine and tyrosine; amino acid residue X₂ is selected from the group consisting of serine, arginine and glutamic acid; and amino acid residue B is selected from the group consisting of serine, arginine and glutamic acid.
3. (previously cancelled)
4. (previously amended) A compound according to claim 58, wherein one of the five amino acid residues is an L amino acid residue and the other four amino acid residues are D amino acid residues.

Appln. Serial No. 09/530,298

3

Docket No. 500862000700

5. (previously amended) A compound according to claim 2, wherein the L-amino acid residue is selected from the group consisting of the amino acid residue O₂, the amino acid residue X₁, and the amino acid residue X₂.
6. (previously amended) A compound according to claim 58, wherein one of the five amino acid residues is a D-amino acid residue and the other four amino acid residues are L-amino acid residues.
7. (original) A compound according to claim 6, wherein the D-amino acid residue is selected from the group consisting of the amino acid residue O₂, amino acid residue X₁, and amino acid residue X₂.
8. (original) A compound according to claim 7, wherein the D-amino acid residue is the amino acid residue O₂.
9. (previously amended) A compound according to claim 58, wherein O₁ is phenylalanine and O₂ is leucine.
10. (previously amended) A compound according to claim 58, wherein O₁ is arginine and O₂ is arginine.
11. (previously amended) A compound according to claim 58, wherein O₁ is glutamine and O₂ is glutamic acid.
12. (previously amended) A compound according to claim 58, wherein O₁ is glutamic acid and O₂ is tryptophan.
13. (previously amended) A compound according to claim 58, wherein O₁ is tryptophan and O₂ is tryptophan.

Appl. Serial No. 09/530,298

4

Docket No. 500862000700

14. (previously amended) A compound according to claim 58, wherein O₁ is tryptophan and O₂ is glutamic acid.
15. (previously amended) A compound according to claim 58, wherein X₁ is tyrosine.
16. (previously amended) A compound according to claim 58, wherein X₂ is glutamic acid.
17. (previously amended) A compound according to claim 58, wherein B is glutamic acid.
18. (previously amended) A compound according to claim 58, wherein O₁ is phenylalanine, O₂ is D-leucine, X₁ is tyrosine, X₂ is glutamic acid, and B is glutamic acid.
19. (previously amended) A compound according to claim 58, wherein the amino acid residue B is a C-terminal amino acid residue.
20. (original) A compound according to claim 19, wherein the affinity group comprises the amino acid sequence -O₁-O₂-X₁-X₂-B-NH₂.
21. (previously amended) A compound according to claim 58, wherein the reactive group comprises a functional group selected from the group consisting of carboxy, phosphoryl, alkyl esters, thioesters, phosphoesters, ortho esters, imidates, mixed anhydrides, amides, thioamine and disulphides.
22. (previously amended) A compound according to claim 21, wherein C_b is absent and the reactive group is bonded directly to the O₁ amino acid residue in the affinity group.
23. (original) A compound according to claim 22, wherein the reactive group is bonded to the O₁ amino acid residue by an amide linkage.

Appln. Serial No. 09/530,298

5

Docket No. 500862000700

24. (previously amended) A compound according to claim 21, wherein the reactive group has the formula $-X-R_1-C(O)-$, wherein R_1 comprises a substituted or unsubstituted aromatic group and X is selected from the group consisting of S, O and N.
25. (original) A compound according to claim 24, wherein X is bonded directly to an aromatic carbon atom in R_1 .
26. (original) A compound according to claim 24, wherein R_1 is unsubstituted phenyl.
27. (previously amended) A compound according to claim 26, wherein -X- and -C(O)- are bonded to the phenyl in a para configuration.
28. (previously amended) A compound according to claim 24, wherein R_1 is phenyl substituted with one or more groups selected from the group consisting of a halogen, NO_2 , SO_2NH_2 , SO_2NHF , CF_3 , CCl_3 , CBR_3 , $C=N$, SO_3H , CO_2H , CHO , OH , $NHCOCH_3$, OCH_3 , CH_3 and CH_2CH_3 .
29. (original) A compound according to claim 24, wherein the reactive moiety is bonded directly to the O_1 residue via the carboxyl carbon.
30. (previously amended) A compound according to claim 21 wherein C_b is present.
31. (previously amended) A compound according to claim 28, wherein C_b is bonded to the reactive group via an ester, thioester, amide, sulfonate ester or sulfonamide linkage.
32. (previously amended) A compound according to claim 30, wherein C_b is bonded to the O_1 amino acid residue in the affinity group via an ester, thioester, amide, sulfonamide, urea, thiourea or carbamate linkage.
33. (previously amended) A compound according to claim 30, wherein C_b comprises a backbone chain of between about 1 and about 25 atoms.

Appln. Serial No. 09/530,298**6****Docket No. 500862000700**

34. (previously amended) A compound according to claim 33, wherein C_b comprises a backbone chain of between about 2 and about 16 carbon atoms.

35. (previously amended) A compound according to claim 30, wherein C_b comprises an unsaturated carbon atom backbone chain of between about 11 and about 25 atoms.

Claims 36-39 (previously cancelled)

40. (previously amended) A compound according to claim 58 wherein C_a is present.

41. (previously amended) A compound according to claim 40, wherein C_a is bonded to E by an ester, thioester, amide, sulfonate ester or sulfonamide linkage.

42. (previously amended) A compound according to claim 40, wherein C_a is bonded to the reactive group by an ester, thioester, amide or sulfonate ester linkage.

43. (previously amended) A compound according to claim 40, wherein C_a comprises a backbone chain of between about 1 and about 25 atoms.

44. (previously amended) A compound according to claim 43, wherein C_a comprises a backbone chain of between about 2 and about 16 carbon atoms.

45. (previously amended) A compound according to claim 40, wherein C_a comprises an unsaturated carbon atom backbone chain of between about 1 and about 25 atoms.

46. (previously amended) A compound according to claim 1, wherein the diagnostic agent comprises biotin.

47. (previously amended) A compound according to claim 46, wherein biotin is bonded directly to the reactive group by an ester, thioester or amide linkage.

Appln. Serial No. 09/530,298

7

Docket No. 500862000700

48. (previously amended) A compound according to claim 46, wherein the reactive group has the formula $-X-Ph-C(O)-$, and wherein X is oxygen, sulfur or nitrogen.
49. (previously amended) A compound according to claim 48, wherein the $-X-$ and $-C(O)-$ on the phenyl group are bonded in a para configuration.
50. (previously amended) A compound according to claim 47 wherein C_a is present.
51. (previously amended) A compound according to claim 50, wherein C_a is bonded to the biotin group by an amide linkage.
52. (previously amended) A compound according to claim 50, wherein C_a is $-NH-(CH_2)_n-C(O)-$, wherein n is an integer between 1 and 25.
53. (previously amended) A compound according to claim 52, wherein C_a is $-NH-(CH_2)_5-C(O)-$.
54. (previously amended) A compound according to claim 52, wherein C_a is $-NH-CH_2-C(O)-$.
55. (original) A compound selected from the group consisting of biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-OPh-C(O)-F/YEE-NH₂, LC-biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-Gly-OPh-C(O)-F/YEE-NH₂, fluorescein-Gly-OPh-F/YEE-NH₂, LC-biotin-OPh-C(O)-F/YEE-NH₂, argatroban-AEA₃-βAla-Gly-OPh-C(O)-F/YEE-NH₂, and fluorescein-thiourea-AEA₃-Gly-OPh-C(O)-F/YEE-NH₂.

Claims 56 and 57 (previously cancelled)

58. (previously introduced) A compound as claimed in claim 1, wherein the target molecule comprises human serum albumin, and the affinity group A comprises a sequence of amino acid

Appln. Serial No. 09/530,298

8

Docket No. 500862000700

residues $-O_1-O_2-X_1-X_2-B-$ wherein the amino acid residues are independently selected from the group consisting of all twenty naturally occurring amino acids in either L or D configuration.

59. (previously introduced) A compound as claimed in claim 1, wherein E is Argatroban, C_a is $AEA_3-\beta Ala-Gly$, R is $-O-Ph-C(O)-$, C_b is absent, and A is $FLYEE-NH_2$.